David G. Hicks

22.1k total citations · 2 hit papers
185 papers, 12.3k citations indexed

About

David G. Hicks is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, David G. Hicks has authored 185 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Oncology, 72 papers in Molecular Biology and 55 papers in Cancer Research. Recurrent topics in David G. Hicks's work include HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (42 papers) and Monoclonal and Polyclonal Antibodies Research (39 papers). David G. Hicks is often cited by papers focused on HER2/EGFR in Cancer Research (62 papers), Breast Cancer Treatment Studies (42 papers) and Monoclonal and Polyclonal Antibodies Research (39 papers). David G. Hicks collaborates with scholars based in United States, China and France. David G. Hicks's co-authors include Patrick L. Fitzgibbons, Daniel F. Hayes, Gail H. Vance, Robert B. Jenkins, M. Elizabeth Hammond, Giuseppe Viale, John M.S. Bartlett, Michael Bilous, Lisa M. McShane and Soonmyung Paik and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

David G. Hicks

180 papers receiving 12.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2013 3.1k citations David G. Hicks et al. profile →
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2013 1.3k citations David G. Hicks et al. Archives of Pathology & Laboratory Medicine profile →

Peers

Countries citing papers authored by David G. Hicks

Since Specialization

Citations

This map shows the geographic impact of David G. Hicks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David G. Hicks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David G. Hicks more than expected).

Fields of papers citing papers by David G. Hicks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David G. Hicks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David G. Hicks. The network helps show where David G. Hicks may publish in the future.

Co-authorship network of co-authors of David G. Hicks

This figure shows the co-authorship network connecting the top 25 collaborators of David G. Hicks. A scholar is included among the top collaborators of David G. Hicks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David G. Hicks. David G. Hicks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Best practices for achieving consensus in HER2‐low expression in breast cancer: current perspectives from practising pathologists 2024 ·Histopathology ·Gary Tozbikian, Marilyn M. Bui, David G. Hicks, Shabnam Jaffer, Thaer Khoury, Hannah Y. Wen, Savitri Krishnamurthy, Shi Wei	4
2	The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations 2023 ·Cancers ·Brian S. Finkelman, Huina Zhang, David G. Hicks, Bradley M. Turner	34
3	The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing 2023 ·Cancers ·Bradley M. Turner, Brian S. Finkelman, David G. Hicks, (unknown), Ioana Moisini, (unknown), Kristin A. Skinner, Mary Ann Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, (unknown), Huina Zhang	1
4	Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression 2023 ·Archives of Pathology & Laboratory Medicine ·Gary Tozbikian, Savitri Krishnamurthy, Marilyn M. Bui, Michael Feldman, David G. Hicks, Shabnam Jaffer, Thaer Khoury, (unknown), Hannah Y. Wen, Paula R. Pohlmann	4
5	Using Health Care Professionals’ Perspectives to Refine a Clinical Decision Support Implementation Strategy for Increasing the Prescribing of HIV Preexposure Prophylaxis (PrEP) in Alabama 2022 ·Journal of the International Association of Providers of AIDS Care (JIAPAC) ·Debbie Humphries, Elizabeth Rhodes, (unknown), Victor Wang, Donna Spiegelman, Corilyn Ott, David G. Hicks, Julia L. Marcus, (unknown), Aadia Rana	4
6	HER2-Low Breast Cancers 2021 ·American Journal of Clinical Pathology ·Huina Zhang, (unknown), Bradley M. Turner, David G. Hicks	63
7	Applying the New Guidelines of HER2 Testing in Breast Cancer 2020 ·Current Oncology Reports ·Huina Zhang, Ioana Moisini, (unknown), Bradley M. Turner, David G. Hicks	34
8	Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma 2018 ·American Journal of Clinical Pathology ·Aaron R. Huber, (unknown), (unknown), (unknown), Loralee McMahon, (unknown), David G. Hicks, Christa L. Whitney‐Miller	10
9	GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma 2014 ·Human Pathology ·Martin J. Edelman, Josephine Feliciano, Binbin Yue, P.A. Bejarano, Olga B. Ioffe, David Reisman, Douglas M. Hawkins, (unknown), David G. Hicks, Ginette Serrero	46
10	Delay to formalin fixation ‘cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry 2012 ·Modern Pathology ·Bryce P. Portier, Zhen Wang, Erinn Downs‐Kelly, J. Jordi Rowe, Deepa T. Patil, (unknown), G. Thomas Budd, David G. Hicks, David L. Rimm, Raymond R. Tubbs	63
11	Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression 2011 ·Cancer Research ·(unknown), (unknown), Kristin A. Skinner, Linda Schiffhauer, James W. Peacock, David G. Hicks, Eileen M. Redmond, D. John Morrow, Alissa Huston, Michelle Shayne, Howard N. Langstein, Carol Miller‐Graziano, Jennifer Strickland, (unknown), Asit K. De	79
12	Predictors of Nipple–Areolar Complex Involvement by Breast Carcinoma: Histopathologic Analysis of 787 Consecutive Therapeutic Mastectomy Specimens 2011 ·Annals of Surgical Oncology ·Jianli Wang, Xiuli Xiao, Jianmin Wang, (unknown), Laurie Baxter, Kristin A. Skinner, David G. Hicks, Steven I. Hajdu, Ping Tang	41
13	ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene 2011 ·Modern Pathology ·Thaer Khoury, (unknown), David G. Hicks, Petr Starostik, Foluso O. Ademuyiwa, (unknown), Richard T. Cheney	6
14	Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17 2010 ·SHILAP Revista de lepidopterología ·(unknown), Jianmin Wang, (unknown), David G. Hicks, Ping Tang	1
15	The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence 2010 ·BMC Cancer ·David G. Hicks, (unknown), (unknown), Swati Kulkarni, Thaer Khoury, Daniel C. Dim, G. Thomas Budd, Brian J. Yoder, Raymond Tubbs, Marshall T. Schreeder, (unknown), Rodney A. Beck, Yanling Wang, Brian Z. Ring, Robert S. Seitz, Douglas T. Ross	31
16	[Molecular phenotypes of breast cancer and their clinical application]. 2009 ·PubMed ·Ping Tang, Bing Wei, David G. Hicks, Kristin A. Skinner, Hong Bu	1
17	HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment 2009 ·The Oncologist ·John J. Barron, Mark J. Cziraky, (unknown), David G. Hicks	26
18	Dual expression of α-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of α-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas 2009 ·Modern Pathology ·(unknown), Ping Tang, Hongwei Zhao, David G. Hicks, Shuyuan Yeh, Xi Wang	12
19	Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. 2008 ·Archives of Pathology & Laboratory Medicine ·David G. Hicks, Swati Kulkarni	38
20	The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course 2005 ·Clinical Cancer Research ·Brian J. Yoder, (unknown), Marek Skacel, (unknown), Shannon Tarr, Thomas Budd, Raymond R. Tubbs, Josephine C. Adams, David G. Hicks	160

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact